Label Changes for:

Vimpat (Lacosamide) Tablets, Injection and Oral Solution

April 2013

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2013

 

ADVERSE REACTIONS

Postmarketing Experience
  • Blood and lymphatic system disorders: Agranulocytosis

 

Hide
(web4)